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The pre-travel medical evaluation of elderly patients and patients with chronic illness
requires special assessment and advice. Screening and special precautions are reviewed for
traveling patients with respiratory disease, cardiac disease, sinusitis, diabetes mellitus, HIV
infection, and other chronic medical conditions. Current guidelines for empiric therapy and
prophylaxis of travelers' diarrhea are reviewed, with emphasis on concerns in geriatric or
chronically ill travelers. Special considerations such as potential drug-drug interactions and
insurance coverage are also discussed.
An increasing number of patients with chronic illness and elderly patients are
becoming world travelers. Safe and healthy travel for such patients involves special
considerations and advice bytheir health care practitioners. This review will address
some issues that arise duringthe pre-travel evaluation forpatientswith illnesses such
as pulmonary or cardiovascular disease, diabetes mellitus, HIV infection, and the
geriatric traveler.
RESPIRATORY DISEASE
A review of altitude considerations is important for advising the patient with
respiratory illness considering air travel. Aircraft cruising altitudes range between
10,000 feet (3,048 meters) to 60,000 feet (18,288 meters) [1]. Aircraft cabins are
pressurized with compressed air but can only maintain a maximum gradient of 445
mm Hg above the outside atmospheric pressure; thus a simulated sea level cabin
pressure cannot be maintained at altitudes higher than 25,500 feet (7,772 meters)
(Table 1) [2]. Cottrell has studied in-flight cabin altitudes and showed that the
simulated altitude in the cabin was significantly higher on newer aircraft (7,411 feet,
2,259 meters) as compared to older aircraft (6,056 feet, 1,846 meters) [3]. The effect
of these cabin altitudes has been shown to decrease arterial oxygen pressures in
healthy volunteers without any associated symptoms [2]. The clinical significance of
cabin altitude-related hypoxemia in patients with chronic lung disease is not fully
known. Several studies have shown that temporary hypoxemia in this setting has not
been associated with any severe symptoms [4,5,6]; however, these studies were done
in stable patients for short exposures.
The pre-travel evaluation for a patient with chronic pulmonary disease who wants
to fly should include a routine history and physical with attention to whether the
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TABLE 1
Altitude Simulation During Air Travel
Aircraft Altitude Simulated Altitude in Cabin
[feet (meters)] [feet (meters)]
40,000 (12,191) 7,500 (2,286)
35,000 (10,667) 5,000 (1,524)
25,500 (7,772) Sea level
15,100 (4,602) Sea level
10,000 (3,048) Sea level
5,000 (1,524) Sea level
Sea level Sea level
Modified from [1]
patient is stable clinically and can exercise adequately without significant dyspnea
[1,7,8]. Jong and Benson have summarized a consensus regarding contraindications
to air travel for those with certain respiratory conditions; however, these are relative
contraindications and may improve with appropriate therapy and supplemental
oxygen (Table 2) [9].
The arterial P02 (PaO2) at cabin altitude is thought to be most important in
considering the need for in-flight supplemental oxygen. Several studies have sug-
gested that the ground-level PaO2 is the most useful predictor of altitude PaO2 in
patientswith normocapnic, stable chronicobstructive pulmonary disease [1,10,4,5,6].
Dillard et al. have shown that including the forced expiratory volume in one second
(FEV1) as a factor improved prediction of the altitude PaO2 significantly [11].
Current recommendations suggest measuring the FEV1 and PaO2 within two weeks
before the flight to predict in-flight PaO2 for patients with normocapnic chronic
obstructive pulmonary disease [1]. Lung function should be maximized by broncho-
TABLE 2






Severe anemia (hemoglobin <8.5 gm/dl or sickling he-
moglobinopathy
Unstable cardiac disease
Thoracic surgery within three weeks
Otitis media, sinusitis, or recent middle ear surgery
Noncommunicating lung cysts
Pneumothorax or pneumomediastinum
Inadequate pulmonary function, including
Hypercapnia (PaCO2 > 50 mm Hg)
Hypoxemia (PaCO2 < 50 mm Hg on room air)
Diffusing capacity <50 percent predicted
aContraindications shouldbeconsidered relative, since
conditions may improve with therapy and supplemen-
tal oxygen.
Modified from [9]
318THE TRAVELER WITH CHRONIC ILLNESS
dilator and steroid therapy as needed. For patients with "borderline" ground-level
PaO2 values of 60 to 70 mm Hg, or patients with co-existing illnesses such as
interstitial lung disease, anemia, cardiac disorders, or other complicating medical
illnesses, evaluation should include an "altitude stress test" in a pulmonary function
laboratory [1,4,6]. The minimal desired in-flight PaO2 for patients with normocapnic
chronic pulmonary disease or these other illnesses is 50 mm Hg, especially when
other medical factors contribute or when the flight lasts longer than two hours [1].
Arrangements for in-flight oxygen must be made with the airline at least 48 hours
prior to departure. Unfortunately, procedures for requesting or administering
oxygen in flight are not currently standardized. Planning non-stop flights and/or
oxygen at destination or stopovers must be considered when making arrangements
[1].
Remind travelers to request a non-smoking seat (as far away as possible from the
smoking section) on international flights in order to avoid elevated carboxyhemoglo-
bin levels. Encourage hydration, since most cabins are maintained at only 8 to 12
percenthumidity and thicksecretionsmaycauseproblemsforpatientswith tracheos-
tomies or chronicbronchitis [9]. Patientswith chronicobstructive pulmonary disease
should carry an extra supply of medications needed for treatment of exacerbations
and keep that supply on their persons rather than in checked baggage.
The above guidelines for decreased oxygenation at high altitudes should also be
considered for those wanting to trek. Those with chronic pulmonary or cardiac
disease should be advised of the remoteness of trekking areas and the lack of
accessible medical care. In general, such patients should avoid treks above interme-
diate (2,000 meters, 6,562feet) or high (4,500 meters, 14,763 feet) altitudes.
CARDIOVASCULAR DISEASE
A study of international air travel from 1977 to 1984 showed that the major cause
(56 percent) of in-flight deaths was unexpected cardiac events [12]. Pre-travel
evaluation of the patient with cardiac or vascular disease also begins with a routine
history and physical. Cardiovascular contraindications to flying include: recent
(within six weeks) myocardial infarction, decompensated congestive heart failure,
uncontrolledarrhythmias, recentcerebrovascularaccident (withintwoweeks), uncon-
trolled hypertension, active thrombophlebitis, and recent deep vein thrombosis
(within four weeks) [8]. Patients with a history of heart disease should have on their
persons, not in checked baggage, a summarized medical history, current electrocar-
diogram, and a supply ofmedications. The American Medical Association Commis-
sion on Emergency Medical Services suggests supplemental oxygen for patients with
chronic cardiovascular disease during flights above 22,500 feet, where potentially
significant hypoxemia can occur [2].
Automaticimplantable cardiacdevices andpacemakers are notconsidered contra-
indications to flight and are not affected by metal detectors used in airport security
[9]. Those with pacemakers should carry the model number and electrocardiogram
with and without pacemaker activation. The international traveler should consider
that telemetry telephone checks are not relayed by satellite.
Deep venous thrombosis (DVT) and pulmonary embolism are of particular
concern in the long-distance traveler, even without a history of cardiovascular
disease [13]. One three-year study at London's Heathrow airport showed that
pulmonary embolism was responsible for 18 percent of sudden deaths in 61 long-
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TABLE 3
Insulin Adjustment for the Diabetic Traveler
Eastbound
Dayofdeparture: Usual dose
First morning ofdestination (local time):
Use 2/3 usual dose
Test glucose level ten hours after A.M. dose:
Give remaining /3 dose ifglucose >240 mg/dl
Westbound
Day ofdeparture: Usual dose
Test glucose level 18 hours after A.M. dose:
Give 1/3 usual A.M. dose ifglucose >240 mg/dl, fol-
lowed by snack or meal
Morning ofdestination (local time):
Usual dose
Modified from [16]
distance travelers [14]. Those at increased risk include the geriatric traveler with
venous disease, venous stasis, ordehydration, andwomen over age 40with aprevious
history ofDVT [13,14].
Travelerswho are predisposed to DVTshould avoid the inside ormiddle seats and
obtain bulkhead seats if possible in order to maximize leg room. They should use
support hose, do isometric calfexercises, and ambulate occasionally. Smokingshould
be avoided, as should dehydration and excess alcohol. Low-dose aspirin or subcuta-
neous heparin may be considered for high-risk patients' who are traveling long
distances [15]. All travelers should maximize hydration with frequent, non-alcoholic
beverages.
DIABETES MELLITUS
Although diabetic patients must take special precautions, there are simple formu-
las to adjust insulin schedules to changes in time zones. Insulin adjustment is not
needed for north-south travel and is only needed for east-west travel if the traveler
crosses more than six time zones. Frequent monitoring by blood testing every six
hours should be advised in the insulin-dependent traveler. For eastbound travel,
adjustment should be made forthe shortened day(Table3). An algorithm byBenson
and Metz [16] suggests decreasing the regular insulin dose to two-thirds on the first
morning of destination at local time, then testing and readjusting ten hours later if
the blood glucose is elevated. Similarly, when the westbound traveler crosses six or
more time zones an adjustment must be made forthe longerday. Ifthebloodglucose
is elevated 18 hours after the A.M. injection, an extra dose of insulin is given (Table
3).
SINUSITIS, OTITIS
Amiddle ear infection or sinus infection is potentially harmful for the air traveler.
Boyle's law (pressure x volume = constant) predicts that, as atmospheric pressure
decreases on ascent, thevolume ofair inbodycavities increasesbythe same amount;
the opposite occurs during descent. As a result, air space in the middle ear and
sinuses will expand during ascent and collapse during descent. When otitis or upper
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respiratory infection is present, the middle ear is especially prone to barotrauma. As
atmospheric pressure increases during descent, the eustachian tube may collapse,
causing rapid accumulation offluid in the middle ear or "aero-otitis media" [17].
Prophylactic topical or systemic decongestants and instruction concerningventila-
tion of the middle ear are the best aids in avoiding barotrauma. The Toynbee
maneuver (pinch nostrils closed and swallow) and a modified Valsalva (hold mouth
and nose closed while increasing nasopharyngeal pressure) can be tried on descent
[17]. Patients with acute sinusitis or otitis media should be discouraged from flying
[2,17].
Early empiric antibiotic treatment ofupper respiratory infections may be advised,
particularly in the patientwith chronic pulmonary disease. Empiric antibiotics which
should be on hand for travelers' diarrhea (see below) might also be used for
bronchitis.
HIV INFECTION
More and more patients with HIV infection, whether they have a clinical diagnosis
ofAIDS or not, are traveling. There are several important considerations in advising
these patients about travel. In the pre-travel medical history, it is appropriate to
inquire regarding HIV-positivity or risk factors for it, since HIV infection is consid-
ered a contraindication to live immunizations, except for measles vaccine. Patients
should receive inactivated rather than live vaccines when these can be substituted,
i.e., enhanced potency inactivated polio vaccine versus live oral polio vaccine.
HIV-positive patients should review their itinerary and travel plans in detailwith the
practitioner because some vaccines are contraindicated. For instance, if travel
involves heavy exposure to mosquitoes in a yellow fever-endemic or -epidemic area
and the patient cannot receive yellow fever (live) vaccine, the traveler should
consider this risk. If travel plans cannot be changed, at least personal protective
measures against mosquitoes can be emphasized. Since patients may inquire, practi-
tioners should inform travelers that, at present, over 50 countries have some sort of
travel restriction for migrants or travelers with HIV infection or AIDS [18,19].
Inform the traveler ofthe need to checkwith the embassy ofthe country or countries
in question, prior to traveling, regarding current policy. In addition to a routine
history and physical to assess the patient's general state of health, immune status
should be evaluated by a CD4 cell count [19]. Special considerations regarding these
patients' susceptibility to enteric pathogens are discussed below (see section on
Travelers' Diarrhea).
Considerations forcontinuing thepatient'smedicalmanagement shouldbe consid-
ered, such as identifying a knowledgeable physician or clinic in the area and
arranging aerosolized pentamidine prophylaxis ifneeded. A physician letter, stating
that the traveler has a chronic illness which may require emergent medical therapy,
may help the traveler to expedite a return home on an airline, should this action be
necessary.
OTHER MEDICAL CONDITIONS
Patients should be questioned about immunosuppression from other conditions,
such as hematologic malignancies or long-term steroid therapy, since live vaccines
are contraindicated in such conditions. Patients over 65 years of age or those with
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chronic illnesses should be up to date on influenza and pneumococcal immuniza-
tions.
The gas expansion that may occur in body cavities makes air travel a risk within
three weeks of intrathoracic surgery [8,20]. Flying should be delayed for one week
after air is introduced into a body cavity for therapeutic or diagnostic reasons [20].
Likewise, a known pneumothorax is a contraindication to air travel [8,17]. Patients
with colostomy bags should be advised about gas expansion during ascent [2] and
wear a larger bag during the flight to allow for this problem.
Nephrologists interviewed at our institution do not report problems related to gas
expansion in the peritoneum in patients on chronic ambulatory peritoneal dialysis
[unpublished observations]. For chronic renal failure patients on hemodialysis,
arrangements for hemodialysis at another unitwhile traveling can often be arranged,
but consideration must be given to the possibility that units may not accept patients
positive for hepatitis B surface antigen. Units may also request hepatitis C or HIV
screening.
Anemic patients with a hemoglobin level less than 8.5 g/dL or sickle-cell disease
should use supplemental oxygen forflights over22,500 feet [2]. Supplemental oxygen
may be considered in the patient with severe cerebrovascular disease, and travel
should be postponed until at least twoweeks after an acute cerebrovascular accident
[20].
Patients with a history of kidney stones, elderly patients, and patients taking
diuretics should be advised about avoiding dehydration when traveling to the tropics.
Elderly patients inparticularshouldbe informedofthe early signs ofheatexhaustion
such as fatigue, weakness, fainting, nausea, vomiting, and headache.
Terminally ill or bedridden patients who want to travel will need to make special
arrangements. The airline carrier with whom travel arrangements are being made
should be contacted for specific and current guidelines.
TRAVELERS' DIARRHEA
Travelers' diarrhea afflicts more than one-third of travelers to the tropics, and
80-85 percent of cases are caused by bacterial pathogens [23]. Enterotoxigenic
Escherichia coli are still the most commonly identified cause of this disease in
travelers to developing countries, accounting for 20-40 percent ofcases [21]. Shigella
sp. accounts for about 8 percent of cases in Latin American countries, and 0-15
percent in Asia and Africa [21]. The rates ofisolation ofnon-typhi Salmonella range
from 0-16 percent in Latin America and 0-33 percent in Asia [21]. S. typhi infections
can also occur, with the highest rates reported from certain countries such as Peru,
India, and Mexico [24]. Campylobacterjejuni infections have been documented in
15-17 percent of cases in studies in Asia; however, it appears to be uncommon as a
cause of "turista" in Mexico [21]. Parasitic infections, such as Giardia lamblia and
Entamoeba histolytica are also important etiologies.
Many patients with chronic illness or elderly patients have special risks for
contracting or developing complications from travelers' diarrhea. Post-gastrectomy
patients or patients taking histamine-blockers may be at increased risk for travelers'
diarrhea, since the host defense of gastric acidity is reduced [25]. Patients taking
diuretics maybecome rapidly dehydrated and electrolyte-depleted. Gastric secretory
failure and decreased intestinal immunity may impair the AIDS patient's host
defense against this disease [26,27]. In addition, Shigella and especially Salmonella
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infections in AIDS patients may be prolonged, severe, and associated with bactere-
mia [28,29,30,31,32]. Campylobacter infections maybe persistent and associated with
cholecystitis or bacteremia in AIDS patients aswell [33,34,35]. Cryptosporidium sp. is
a relatively uncommon cause of travelers' diarrhea and not a significant one in
healthy travelers, since most infections are self-limited; however, it can cause a
chronic, wasting diarrhea in AIDS patients. For these patients, preventive measures
to avoid travelers' diarrhea and empirictherapydirected at the most common causes,
should the traveler develop symptoms, are especially important.
The best way to prevent travelers' diarrhea is to avoid contaminated food and
water. Food served steaming hot or food that can be peeled is considered safe.
Bottled water or beverages, particularly if carbonated, are probably safe from
contamination. Ice is not safe and should be avoided. Water purification is difficult.
Boiling water for ten minutes kills bacteria, viruses, and protozoa and is considered
the best method. Iodide tablets, when used according to directions, eliminate
bacteria and viruses, but these tablets do not reliably inactivate protozoa such as G.
lamblia [36]. Filtration systems can eliminate both bacteria and protozoa, but theydo
not usually filter viruses that may be pathogenic for travelers, such as hepatitis A or
rotavirus. Good filtration systems are also expensive and may not be practical for the
traveler who is not planning a number of exotic sojourns. Avoiding contaminated
food and water is difficult at best. One study documents that travelers do not or
cannot complywith the adage, "Boil it, cook it, peel it, orforget it" [37].
Agents used for empiric therapy include trimethoprim/sulfamethoxazole, fluoro-
quinolones (ciprofloxacin, norfloxacin, ofloxacin), doxycycline, andbismuth subsalic-
ylate. Trimethoprim/sulfamethoxazole (TMP/SMX) (800/160 mg orally twice daily
for three days) has been effective empiric therapy for travelers' diarrhea and, when
combined with the anti-motility agent loperamide, can limit symptoms to one hour's
duration [38]. In that study of travelers to Mexico, the combination of TMP/SMX
plus loperamide was more effective than either drug alone, although both drugs
alone were more effective than a placebo. Increasing antibiotic resistance to TMP/
SMX among enteric pathogens in developing countries [39,19] has raised a concern
about using TMP/SMX as empiric therapy, now that fluoroquinolone agents are
available. Another potential advantage of the fluoroquinolones is their activity
againstTMP/SMX-resistantSalmonella sp. and activityagainstCampylobacterjejuni,
which TMP/SMX does not have. For AIDS patients at a greater risk from these
infections or for travelers going to areas where these are more prevalent causes of
diarrhea, one of the fluoroquinolones may be the best choice for empiric therapy.
Ciprofloxacin (500 mg twice daily for three days) or norfloxacin (400 mg twice daily
for three days) are effective therapy. When ciprofloxacin plus loperamide was
compared with ciprofloxacin alone in a study of travelers' diarrhea in Egypt, there
was a trend for those using combination therapy to have shorter duration of
symptoms, although this trend did not achieve statistical significance except in
patients with enterotoxigenic E. coli [40]. Loperamide alone is not usually recom-
mended because ofthe high failure rate (13 percent) in astudyoftravelers to Mexico
[38], and because of adverse effects reported when another antimotility agent,
diphenoxylate hydrochloride, has been used alone to treat shigellosis [41]. Doxycy-
cline hydrochloride may also be used as empiric therapy (100 mg twice daily for five
days), but the antimicrobial resistance to tetracyclines in developing countries and
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TABLE 4
Travelers' Diarrhea Empiric Therapy
Agent Considerations Contraindications
Quinolones Broad-spectrum Pregnancy
Ciprofloxacin Theophyllines (Ciprofloxacin) Children
Norfloxacin
Ofloxacin
Trimethoprim/ Bacterial resistance in many areas Pregnancy
Sulfamethoxazole Photosensitivity HIV-positive
Hypersensitivity (especially HIV-positive)
Doxycycline Photosensitivity (15 percent) Pregnancy
Vaginitis Children
Loperamide Should be used in combination with empiric antibiotic Fever
Severe abdominal pain
Bismuth Subsalicylate Large doses required Pregnancy
Tinnitus
Black stools
the photosensitivity that occurs in 15 percent of patients make this choice an
undesirable agent whenvisiting a tropical country.
Bismuth subsalicylate has also been shown to be effective empiric therapy. The
advantages of this agent are that it is safe and well-tolerated. Patients should be
advised about black stools and potential tinnitus. The disadvantage of this agent is
that large doses (in tablet or liquid form) must be given (525 mg in eight half-hourly
doses for the first 24 hours, continuing for 48 hours or until symptoms are gone), and
that antimicrobials are more effective for dysenteric cases ofdiarrhea [42].
Drug interactions and contraindications should be considered when choosing
empiric therapy. Patients on oral hypoglycemic agents should avoid taking TMP/
SMX, since it can potentiate these agents to cause profound hypoglycemia [43,44].
Patients on theophyllines should avoid ciprofloxacin and norfloxacin, which prolong
the half-life of theophyllines and xanthines. If a fluoroquinolone is still desirable,
ofloxacin, another fluoroquinolone with a similar spectrum of activity but without
theophylline interaction, maybe considered. Oral rehydration is an important aspect
oftherapy. Oral electrolyte andglucose packetscanbe taken along and reconstituted
when necessary.
Prophylactic antibiotics are not currently recommended for routine travelers due
to toxicity from drug-related side effects, the availability of rapidly effective empiric
therapies, a false sense of security in the traveler, and difficulty in identifying agents
for empiric therapy should the travelers on antibiotics become ill [23,45]. There are
also concerns about the development of antibiotic resistance in fecal flora while on
TMP/SMX or doxycycline [39]. One study has shown that development ofresistance
did not occur when norfloxacin was used as prophylaxis for a two-week period in
Mexico [46]. Undesirable side effects include skin rashes, photosensitivity, vaginal
candidiasis, and antibiotic-associated colitis. Chemoprophylaxis has been shown to
be effective, however [47,48], and, in certain situations, it may be more cost-effective
than empiric therapy [49]. Agents currently used include TMP/SMX (160 mg/800
mg), norfloxacin (400 mg), ciprofloxacin (500 mg), ofloxacin (100 mg), doxycycline
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(100 mg) once daily while in the high-risk area [23]. Bismuth subsalicylate may also
be effective in doses of two 525 mg tablets four times daily [23]. Chemoprophylaxis
may be considered in the patient in whom diarrhea would be disastrous even for a
few hours [23,50]. No traveler should take prophylaxis for a visit to a high-risk area
that lasts longer than three weeks because of the chance of development of
antibiotic-resistant flora or adverse side effects [23].
ADVERSE DRUG EFFECTS
Since chronically ill and geriatric patients are often on numerous medications, it is
important to consider potential drug interactions that may occur on the trip.
Interactions of antibiotics used for empiric therapy of travelers' diarrhea are
discussed above. Other interactions to consider are those that may occur with
antimalarials used for prophylaxis. For example, mefloquine can decrease cardiac
conduction and is contraindicated in patients taking beta-blockers or quinidine.
Anticholinergic drugs such as scopolamine, used for prevention of motion sickness,
should be given with care to the elderly, who are more susceptible to the potential
side effects ofconfusion and disorientation. Anticholinergic drugs also decrease the
ability to sweat and may further predispose this group to heat syndromes.
OTHER CONSIDERATIONS
Patients should review their medical insurance to see ifcoverage extends overseas.
Except for some cruises in U.S. territorial waters and certain inpatient services in
Canada and Mexico, Medicare does not usually cover services in othercountries [51].
The traveler should check Medicare coverage for the specific destination before
departure. There are a number of travel insurance plans available which include
medical coverage and air evacuation for emergency departure; travelers with health
problems should consider these. Some countries require a physician letter for a visa
application if the traveler is over age 65. The U.S. embassy should be consulted for
up-to-date information.
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